Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Lessons learnt from the ACCOAST-trial
Restricted accessResearch articleFirst published online June, 2016
Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Lessons learnt from the ACCOAST-trial
The optimal time-point of the initiation of P2Y12 antagonist therapy in patients with non-ST elevation acute coronary syndromes (NTSE-ACS) is still a matter of debate. European guidelines recommend P2Y12 as soon as possible after first medical contact. However, the only trial which compared the two strategies did not demonstrate any benefit of pre-treatment with prasugrel before angiography compared to starting therapy after angiography and just prior to percutaneous coronary intervention (PCI). This paper summarizes the results of pharmacodynamic and previous studies, and gives recommendations for the initiation of P2Y12 antagonist therapy in NSTE-ACS in different clinical situations.
HammCWBassandJPAgewallS. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J2011; 32: 2999–3054.
2.
StegGJamesSKAtarD. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J2012; 33: 2569–2619.
YusufSZhaoFMehtaSR. Effects of clopidogrel in addition to aspirin inpatients with acute coronary syndromes without ST-segment elevation. N Engl J Med2001; 345:494–502.
5.
MontalescotGSiderisGMeulemannC. A randomized comparison of high clopidogrel loading doses in patients with non-ST segment elevation acute coronary syndromes. The ALBION trial. J Am Coll Cardiol2006; 48: 931–938.
6.
WiviottSDBraunwaldEMcCabeCH. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med2007; 357: 2001–2015.
7.
MontalescotGBologneseLDudekD. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Me. 2013; 369: 999–1010.
8.
AradiDStoreyRFKomocsiA., on behalf of the Working Group on Thrombosis of the European Society of Cardiology. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J2014; 35(4): 209–215.
9.
SilvainJCaylaGHulotJ-S. High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. Eur Heart J2012; 33: 1241–1249.
10.
ColletJPSilvainJLandivierA. Dose-effect of clopidogrel re-loading in patients already on 75mg maintenance dose: the RELOAD study. Circulation2008; 118: 1225–1233.
11.
KastratiAvon BeckerathNJoostA. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation2004; 110: 1916–1919.
12.
Di SciascioGPattiGPasceriV. Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. J Am Coll Cardiol2010; 56: 550–557.
13.
AradiDKomócsiAPriceMJ. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. Int J Cardiol2013; 167: 2140–2148.
14.
ColletJ-PCuissetTRangéG. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med2012; 367: 2100–2109.
15.
PriceMJBergerPBTeirsteinPS. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA2011; 305: 1097–1105.
16.
GurbelPABlidenKPButlerK. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation2009; 120: 2577–2585.
17.
WiviottSDTrenkDFrelingerAL. for the PRINCIPLE-TIMI 44 investigators. Prasugrel compared to high loading and maintenance dose clopidogrel in patients with planned percutaneous coronary intervention: The PRINCIPLE-TIMI 44 Trial. Circulation2007; 116: 2923–2932.
18.
AngiolilloDJSaucedoJFDeraadR. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol2010; 56: 1017–1023.
19.
MontalescotGSiderisGCohenA. on behalf of the ACAPULCO investigators. Prasugrel 10 mg provides greater platelet inhibition than clopidogrel 900/150 mg in UA/NSTEMI ACS - The ACAPULCO study. Eur Heart J2008; 29(Supplement European Society of Cardiology Congress, Munich, 2008): 746 (Abstract 4408).
20.
StoneGWWitzenbichlerB and the ADAPT-DES investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet2013; 382: 614–623.
21.
KerneisMSilvainJAbtanJ. Switching acute coronary syndrome patients from prasugrel to clopidogrel. JACC Cardiovasc Interv2013; 6: 158–165.
22.
GiuglianoRPWhiteJABodeC. Early versus delayed, provisional eptifiba- tide in acute coronary syndromes. N Engl J Med2009; 360: 2176–2190.
23.
MehtaSRYusufSPetersRJ. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet2001; 358: 527–533.
24.
PuyrimatEBattlerABirkheadJ. Euro Heart Survey 2009 Snapshot: regional variations in presentation and management of patients with AMI in 47 countries. Eur Heart J Acute Cardiac Care2013; 2: 359–370.
25.
WallentinLBeckerRCBudajA. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med2009; 361: 1045–1057.
26.
WidimskyPMotovskáZSimekS. Clopidogrel pre-treatment in stable angina: for all patients > 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. Eur Heart J2008; 29: 1495–1503.
27.
Bellemain-AppaixAO’ConnorSASilvainJ. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. JAMA2012; 308: 2507–2516.
28.
Bellemain-ApaixAKerneisMO’ConnorSA. Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. BMJ2014;349: g6269.
29.
MontalescotGColletJ-PEcollanP. Effect of Prasugrel Pre-Treatment Strategy in Patients Undergoing Percutaneous Coronary Intervention for NSTEMI: The ACCOAST-PCI Study. J Am Coll Cardiol2014; 64: 2563–2571.
30.
LindholmDVarenhorstCCannonCP. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J2014; 35: 2083–2093.
